Angiogenesis: novel and basic science insights and human therapy - keystone symposium.
Iruela-Arispe
Luisa
L
University of California Los Angeles, Department of Molecular, Cell & Developmental Biology, 555A MBI Building, Los Angeles, CA 90095, USA. arispe@mbi.ucla.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D004351:Drug Resistance; D005128:Eye Diseases / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D014157:Transcription Factors / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology; D000099200:Scaffold Protein ILK
D020533:Angiogenesis Inhibitors; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D017346:Protein Serine-Threonine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; D000099200:Scaffold Protein ILK; C497442:HIF1A protein, human